13. **Gelb AF**, Flynn-Taylor C, Nussbaum E, *et al.* Airway and alveolar nitric oxide inflammation in treated asthma. *Am J Respir Crit Care Med* 2004;**170**:737–41.
14. **Gelb AF**, Flynn Taylor C, Shinar CM, *et al.* Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics. *Chest* 2006;**129**:1492–9.
15. **Lehtimäki L**, Kankaanranta H, Saarelainen S, *et al.* Inhaled fluticasone decreases bronchial but not alveolar nitric oxide output in asthma. *Eur Respir J* 2001;**18**:635–9.
16. **van Veen IH**, Sterk PJ, Schot R, *et al.* Alveolar nitric oxide versus measures of peripheral airway dysfunction in severe asthma. *Eur Respir J* 2006;**27**:951–6.
17. **Berry M**, Hargadon B, Morgan A, *et al.* Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. *Eur Respir J* 2005;**25**:986–91.
18. **Mahut B**, Delacourt C, Zerah- Lancner F, *et al.* Increase in alveolar nitric oxide in the presence of symptoms in childhood asthma. *Chest* 2004;**125**:1012–18.
19. **Paraskakis E**, Brindicci C, Fleming L, *et al.* Measurement of bronchial and alveolar nitric oxide production in normal children and children with asthma. *Am J Respir Crit Care Med* 2006;**174**:260–67.
20. **Brindicci C**, Ito K, Barnes PJ, Kharitonov SA. Differential flow analysis of exhaled nitric oxide in patients with asthma of differing severity. *Chest* 2007;**131**:1353–62.
21. **Shin HW**, Rose-Gottron CM, Cooper DM, *et al.* Airway diffusing capacity of nitric oxide and steroid therapy in asthma. *J Appl Physiol* 2004;**96**:65–75.
22. **Condoirelli P**, Shin HW, Aledia AS, *et al.* A simple technique to characterize proximal and peripheral nitric oxide exchange using constant flow exhalations and axial diffusion model. *J Appl Physiol* 2007;**102**:417–25.
23. **Silkoff PE**, McClean PA, Slutsky AS, *et al.* Marked flow-dependence of exhaled nitric oxide using a new technique to exclude nasal nitric oxide. *Am J Respir Crit Care Med* 1997;**155**:260–7.
24. **Gelb AF**, Hogg JC, Muller NL, *et al.* Contribution of emphysema and small airways in COPD. *Chest* 1996;**109**:353–9.
25. **Lehtimäki L**, Kankaanranta H, Saarelainen S, *et al.* Extended exhaled NO measurement differentiates between alveolar and bronchial inflammation. *Am J Respir Crit Care Med* 2001;**163**:1557–61.
26. **Hyde RW**, Geigel EJ, Olszowska AJ, *et al.* Determination of production of nitric oxide by lower airways of humans—theory. *J Appl Physiol* 1997;**82**:1290–6.
27. **Kerckx Y**, Van Muylem A. Axial distribution heterogeneity of nitric oxide airway production in healthy adults. *J Appl Physiol* 2009;**106**:1832–9.
28. **Verbanck S**, Kerckx Y, Schuermans D, *et al.* Effect of airways constriction on exhaled nitric oxide. *J Appl Physiol* 2008;**104**:909–11.
29. **Wenzel SE**, Schwartz LB, Langmack EL, *et al.* Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. *Am J Respir Crit Care Med* 1999;**160**:1001–8.
30. **Haldar P**, Pavord ID. Noneosinophilic asthma: a distinct clinical and pathologic phenotype. *J Allergy Clin Immunol* 2007;**119**:1043–52.
31. **Global strategy for asthma management and prevention**. <http://www.ginasthma.org>.
32. **Szeffler SJ**, Mitchell H, Sorkness CA, *et al.* Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomized controlled trial. *Lancet* 2008;**372**:1065–72.
33. **de Jongste JC**, Carraro S, Hop WC, *et al.* Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. *Am J Respir Crit Care Med* 2008;**179**:93–7.
34. **Shaw DE**, Berry MA, Thomas M, *et al.* The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. *Am J Respir Crit Care Med* 2007;**176**:231–7.
35. **Pijnenburg MW**, Bakker EM, Hop WC, *et al.* Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. *Am J Respir Crit Care Med* 2005;**172**:831–6.
36. **Smith AD**, Cowan JO, Brassett KP, *et al.* Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. *N Engl J Med* 2005;**352**:2163–73.
37. **Berry MA**, Shaw DE, Green RH, *et al.* The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. *Clin Exp Allergy* 2005;**35**:1175–9.
38. **Gelb AF**, Taylor CF, Krishnan A, *et al.* Central and peripheral airway sites of nitric oxide gas exchange in COPD. *Chest* 2010;**137**:575–84.

Lung alert

Non-invasive ventilation (NIV) immediately after extubation reduces ventilatory failure and 90-day mortality in patients with hypercapnia

This randomised open controlled trial took place from 2005–7 in three Spanish intensive care units. The aim was to assess whether non-invasive ventilation (NIV) would prevent respiratory failure and hence re-intubation, an independent risk factor for mortality, nosocomial pneumonia and length of hospital stay in patients who developed hypercapnia (arterial carbon dioxide tension >45 mm Hg) during a spontaneous breathing trial prior to extubation. The secondary end point was 90-day mortality.

One hundred and sixty-four consecutive patients were registered and 106 underwent randomisation. Fifty-four were assigned NIV (mean pressure 17/4 cm H₂O) immediately after extubation for a maximum of 24 h while the control group was given oxygen alone. Both groups were monitored for ventilatory failure and, if found, were either managed with re-intubation or rescue NIV according to predefined criteria.

Statistically significant differences in the development of respiratory failure were found in the NIV group compared with the controls (15% vs 48%), the impact occurring within the first 24 h. There was, however, no difference in the rate of re-intubation or in the length of stay in hospital or in the intensive care unit (ICU). This may have been a result of rescue NIV being deployed in both groups; 20/25 controls in respiratory failure met the criteria for rescue NIV, leading to 75% avoiding re-intubation, a better outcome than in previous reports.

Although overall mortality in the ICU and hospital did not differ, 90-day mortality was significantly reduced in the NIV group, suggesting longer term benefits of NIV which cannot be explained by re-intubation avoidance alone and warrants further assessment.

► **Ferrer M**, Sellares J, Valencia M, *et al.* Non-invasive ventilation after extubation in hypercapnic patients with chronic respiratory disorders: randomised controlled trial. *Lancet* 2009;**374**:1082–8.

I Stone

The Royal London Hospital, London, UK

Correspondence to Dr I Stone, The Royal London Hospital, Whitechapel, London E1 1BB, UK; ian.stone@bartsandthelondon.nhs.uk

Thorax 2010;**65**:625. doi:10.1136/thx.2010.141077